Jazz Pharmaceuticals Submits Marketing Authorization Application to European Medicines Agency for Solriamfetol as a Treatment to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adult Pa
Go back to Jazz Pharmaceuticals Submits Marketing Authorization Application to European Medicines Agency for Solriamfetol as a Treatment to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adult Pa| JAZZ PHARMACEUTICAL (NASDAQ: JAZZ) | Delayed: 225.92 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $225.92 | 52 Week High | $160.00 | |||
| Open | $225.92 | 52 Week Low | $95.80 | |||
| Day High | $225.92 | P/E | 41.99 | |||
| Day Low | $225.92 | EPS | $5.38 | |||
| Volume | 57 | |||||
